📊 MIRA Key Takeaways
Is Mira Pharmaceuticals, Inc.. (MIRA) a Good Investment?
Mira Pharmaceuticals is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial performance. The company generated only $98.9K in revenue (down 40% YoY) while operating losses widened, with net losses of $10.4M consuming cash at an unsustainable rate. At current burn rate, the company's $6.3M cash position provides less than 2 quarters of runway, creating critical going concern risk without immediate capital injection or dramatic operational changes.
MIRA Pharmaceuticals shows very weak operating fundamentals: revenue is minimal and declining, net losses remain extremely large relative to sales, and operating cash flow is deeply negative. The balance sheet is currently a mitigating factor, with strong cash, high liquidity, and essentially no debt, but the business still appears dependent on external funding unless it materially improves commercialization or clinical progress.
Why Buy Mira Pharmaceuticals, Inc.. Stock? MIRA Key Strengths
- Strong liquidity position with $6.3M cash and 15.75x current ratio
- Minimal debt burden with no long-term debt obligations
- Pharmaceutical sector offers high-value commercialization potential if pipeline succeeds
- Strong liquidity position with $6.35M in cash and a 15.75x current ratio
- Very low leverage, with negligible debt and over $10M in equity
- Asset base is largely funded by equity rather than liabilities, reducing near-term balance sheet stress
MIRA Stock Risks: Mira Pharmaceuticals, Inc.. Investment Risks
- Severe revenue decline (-40% YoY) indicates failed market traction or product commercialization
- Net loss of $10.4M with only $98.9K revenue creates unsustainable -10,557% net margin
- Operating cash burn of $4.7M quarterly with limited runway; cash will deplete within 6 quarters at current rates
- No insider buying activity in 90 days suggests lack of management confidence
- Early-stage pharmaceutical companies with minimal revenue face existential risk of capital exhaustion
- Revenue is tiny and fell 40.3% year over year, indicating weak commercial traction
- Net margin of -10557.5% and negative operating cash flow of $4.66M point to an unsustainable earnings profile
- Likely need for future capital raises if cash burn continues without meaningful revenue growth
Key Metrics to Watch
- Quarterly revenue and revenue growth trajectory
- Monthly cash burn rate and months of runway remaining
- Operating loss trends and path to profitability timeline
- Pipeline advancement milestones and regulatory progress
- Capital raising announcements and dilution impact
- Quarterly operating cash burn relative to cash balance
- Revenue growth and any improvement in net loss margin
Mira Pharmaceuticals, Inc.. (MIRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.75x current ratio provides a solid financial cushion.
MIRA Profit Margin, ROE & Profitability Analysis
MIRA vs Healthcare Sector: How Mira Pharmaceuticals, Inc.. Compares
How Mira Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mira Pharmaceuticals, Inc.. Stock Overvalued? MIRA Valuation Analysis 2026
Based on fundamental analysis, Mira Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mira Pharmaceuticals, Inc.. Balance Sheet: MIRA Debt, Cash & Liquidity
MIRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mira Pharmaceuticals, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
MIRA Revenue Growth, EPS Growth & YoY Performance
Mira Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
MIRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mira Pharmaceuticals, Inc.. (CIK: 0001904286)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MIRA
What is the AI rating for MIRA?
Mira Pharmaceuticals, Inc.. (MIRA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIRA's key strengths?
Claude: Strong liquidity position with $6.3M cash and 15.75x current ratio. Minimal debt burden with no long-term debt obligations. ChatGPT: Strong liquidity position with $6.35M in cash and a 15.75x current ratio. Very low leverage, with negligible debt and over $10M in equity.
What are the risks of investing in MIRA?
Claude: Severe revenue decline (-40% YoY) indicates failed market traction or product commercialization. Net loss of $10.4M with only $98.9K revenue creates unsustainable -10,557% net margin. ChatGPT: Revenue is tiny and fell 40.3% year over year, indicating weak commercial traction. Net margin of -10557.5% and negative operating cash flow of $4.66M point to an unsustainable earnings profile.
What is MIRA's revenue and growth?
Mira Pharmaceuticals, Inc.. reported revenue of $98.9K.
Does MIRA pay dividends?
Mira Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find MIRA SEC filings?
Official SEC filings for Mira Pharmaceuticals, Inc.. (CIK: 0001904286) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIRA's EPS?
Mira Pharmaceuticals, Inc.. has a diluted EPS of $-1.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Mira Pharmaceuticals, Inc.. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIRA stock overvalued or undervalued?
Valuation metrics for MIRA: ROE of -100.5% (sector avg: 15%), net margin of -10,557.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIRA stock in 2026?
Our dual AI analysis gives Mira Pharmaceuticals, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIRA's free cash flow?
Mira Pharmaceuticals, Inc..'s operating cash flow is $-4.7M, with capital expenditures of N/A. FCF margin is -4,713.0%.
How does MIRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,557.5% (avg: 12%), ROE -100.5% (avg: 15%), current ratio 15.75 (avg: 2).